Vertical transmission of HIV--a rediscussion of testing. NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Vertical transmission of HIV--a rediscussion of testing.

AIDS Care. 1995;7(5):657-62. Unique Identifier : AIDSLINE MED/96263771
Macquart-Moulin G; Hairion D; Auquier P; Manuel C; INSERM Research Unit, Institut Paoli-Calmettes, Marseille,; France.

Abstract: It is worthwhile reconsidering the debate on mandatory or voluntary testing for HIV antibody among women of childbearing age, in the light of recent virological and therapeutic discoveries that have altered the parameters of the issue. The therapeutic possibilities of reducing the risk of transmission for women confirmed as seropositive are an incontestable benefit for anyone who is aware of her serological status; the fact of being able to detect real infection at birth could mean that causing unnecessary distress to the antibody positive but uninfected newborn infant is avoided. Medical professionals now have convincing arguments to persuade women at risk to accept the test when it is offered. But, in any case, the voluntary nature of the decision for testing must be respected.
Keywords: AIDS Serodiagnosis Disease Transmission, Vertical/*PREVENTION & CONTROL *Ethics, Medical Female Health Services Accessibility Human HIV Infections/DRUG THERAPY/*PREVENTION & CONTROL/*TRANSMISSION *Infant Care Infant, Newborn Patient Acceptance of Health Care Pregnancy Pregnancy Complications, Infectious/DRUG THERAPY/*PREVENTION & CONTROL Prejudice *Prenatal Care Prognosis Risk Factors Zidovudine/THERAPEUTIC USE JOURNAL ARTICLEKWDaidsserodiagnosisdiseasetransmission,vertical/KWDprevention&controlKWDethics,medicalfemalehealthservicesaccessibilityhumanhivinfections/drugtherapy/KWDprevention&control/KWDtransmissionKWDinfantcareinfant,newbornpatientacceptanceofhealthcarepregnancypregnancycomplications,infectious/drugtherapy/KWDprevention&controlprejudiceKWDprenatalcareprognosisriskfactorszidovudine/therapeuticusejournalarticle
961030
M96A1445

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .